Dendritic cell therapy uses a personalized vaccine to train the immune system to recognize glioblastoma cells. This autologous treatment involves extracting patient monocytes, maturing them with tumor antigens in a laboratory, and re-injecting them to trigger a targeted T-cell response against remaining brain cancer cells.
- Cell collection: Doctors perform leukapheresis to harvest monocytes from 150ml of blood.
- Laboratory education: Technicians pulse mature dendritic cells with specific tumor antigens.
- Vaccination schedule: Patients receive processed cells via intradermal injections over several weeks.
- Immune activation: Primed cells migrate to lymph nodes to activate tumor-killing T-cells.
- German providers: Expert centers include Nordwest Clinic in Frankfurt and IOZK in Cologne.
Bookimed Expert Insight: Data suggests combining dendritic cell therapy with specialized surgical centers increases effectiveness. Prof. Dr. Peter Vajkoczy at Charité performs over 4,000 surgeries annually, ensuring the low tumor burden required for immunotherapy success. Leading centers like Nordwest Clinic utilize Focus-listed specialists like Prof. Elke Jäger to pioneer these therapeutic individual antitumor vaccines.
Patient Consensus: Patients emphasize that this therapy works best after maximal safe surgery rather than as a standalone treatment. Many note that while infusions are easy to tolerate, regular MRI monitoring every 3 months is essential to track stability.
